The Role of Combination Therapies
A key trend in the Anti-VEGF Market is the increasing use of combination therapies. While anti-VEGF monotherapy has been highly effective, some patients, particularly those with advanced or complex conditions, may not respond optimally. In these cases, combining anti-VEGF drugs with other treatments, such as steroids or other targeted therapies, can lead to better outcomes. In ophthalmology, for example, combination therapies may be used to address both abnormal blood vessel growth and the associated inflammation.
In oncology, anti-VEGF drugs are almost always used in combination with other treatments to maximize their effectiveness and to overcome potential resistance mechanisms. The development of new combination therapies is a major area of research and is expected to drive innovation in the market. This approach recognizes the complex, multi-faceted nature of the diseases being treated and offers a more comprehensive solution for patients.